Search - tctmd.com

Displaying 1 - 20 of 84

Sort: Relevancy | Date

News Features

Top News in Prevention: 2018

Michael O'Riordan

December 28, 2018

News Features

Top News in Policy & Practice: 2018

Todd Neale

December 28, 2018

News Features

Top News in Endovascular Therapy: 2018

L.A. McKeown

December 28, 2018

News Features

Top News in Clinical Cardiology: 2018

Yael L. Maxwell

December 28, 2018

News Daily News

FOURIER Analysis: Evolocumab Delivers Consistent LDL Cholesterol-Lowering

Yael L. Maxwell

December 19, 2018

News Daily News

Now You See It: Imaging Helps Lower CVD Risk Burden in Primary Prevention

Michael O'Riordan

December 10, 2018

News Daily News

Benefits of Statins Only Exceed Harms at Higher 10-Year Risk Thresholds, Study Suggests

Michael O'Riordan

December 03, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2018

Shelley Wood

November 30, 2018

News Daily News

Angina Without Obstructive Stenosis: No Longer a ‘Black Box’ Mystery, Say Experts

Michael O'Riordan

November 23, 2018

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

News Conference News AHA 2018

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

Caitlin E. Cox

November 13, 2018

News Conference News AHA 2018

Sit Less, Move More: New Physical Activity Guidelines Stress Movement at All Ages

Michael O'Riordan

November 12, 2018

Presentation AHA 2018

Safety and Efficacy of AKCEA-APO(a)-LRx to Lower Lipoprotein(a) Levels in Patients With Established Cardiovascular Disease: A Phase 2 Dose-Ranging Trial

Presenter: Sotirios Tsimikas

November 11, 2018

News Conference News AHA 2018

Novel Inhibitor of Apolipoprotein(a) Production Lowers Lp(a) in Phase II Study

Shelley Wood

November 11, 2018

News Conference News AHA 2018

New Cholesterol Guidelines Make Room for Non-Statin Therapy and CAC Screening

Michael O'Riordan

November 10, 2018

News Daily News

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Michael O'Riordan

November 07, 2018

News Daily News

Statins Provide No Clinical Benefit When Coronary Calcium Is Zero, Study Shows

Michael O'Riordan

November 06, 2018

News Conference News AHA 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

Shelley Wood

November 05, 2018

News Daily News

Final Phase III Bempedoic Acid Trial Proves Positive for LDL-Lowering

Shelley Wood

October 29, 2018

News Daily News

Price Chop for Evolocumab: PCSK9 Inhibitor Cost Cut by 60%

Michael O'Riordan

October 25, 2018

Advertisement

Top News in Prevention: 2018

Top News in Policy & Practice: 2018

Top News in Endovascular Therapy: 2018

Top News in Clinical Cardiology: 2018

FOURIER Analysis: Evolocumab Delivers Consistent LDL Cholesterol-Lowering

Now You See It: Imaging Helps Lower CVD Risk Burden in Primary Prevention

Benefits of Statins Only Exceed Harms at Higher 10-Year Risk Thresholds, Study Suggests

TCTMD’s Top 10 Most Popular Stories for November 2018

Angina Without Obstructive Stenosis: No Longer a ‘Black Box’ Mystery, Say Experts

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

Sit Less, Move More: New Physical Activity Guidelines Stress Movement at All Ages

Safety and Efficacy of AKCEA-APO(a)-LRx to Lower Lipoprotein(a) Levels in Patients With Established Cardiovascular Disease: A Phase 2 Dose-Ranging Trial

Novel Inhibitor of Apolipoprotein(a) Production Lowers Lp(a) in Phase II Study

New Cholesterol Guidelines Make Room for Non-Statin Therapy and CAC Screening

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Statins Provide No Clinical Benefit When Coronary Calcium Is Zero, Study Shows

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

Final Phase III Bempedoic Acid Trial Proves Positive for LDL-Lowering

Price Chop for Evolocumab: PCSK9 Inhibitor Cost Cut by 60%

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content